Multimodal Management for Perioperative Analgesia for the Reduction of Opioid Use for Pain in Head and Neck Free Flap Patients
This clinical trial tests the addition of regional nerve blocking agents (ropivacaine or bupivacaine) to standard of care pain management in reducing opioid use for managing pain after free flap reconstruction surgery following removal of head and neck cancer. Free flap reconstruction following surgical removal of head and neck cancer is a complex process that requires close monitoring and management following the procedure. Pain control during the immediate and long-term recovery period is important for patient well-being, quality of life, and success. However, many different pain medications can be used in this time, and there are no studies that have demonstrated the best combination of medications for patients undergoing this type of surgery. Opioids are a class of drugs that include strong prescription pain relievers such as oxycodone, hydrocodone, and fentanyl. Given the increase in opioid use in the United States and the various side effects and risk of addiction that comes with it, it is important to identify different strategies to mitigate opioid use and improve overall pain management in patients. Giving a regional nerve blocking agent (ropivaciane or bupivacaine) may help decrease pain and reduce opioid usage after surgery, which may reduce the risk of constipation and prolonged opioid dependency.